ASPIRIN 2015

Dr Langley, who is the principal investigator of the Add-Aspirin trial, talks to ecancer about the rationale and opportunities for using aspirin as an adjuvant agent in the treatment of solid tumours at the 2015 Scientific Conference of the International Aspirin Foundation.

Professor Rothwell talks to ecancertv about the work of the International Aspirin Foundation and presentations at its 2015 Scientific Conference held August 28th in London, UK. In the interview he comments on presentations that centred on common mechanisms of disease and their modulation by aspirin. He also discusses his experience of using aspirin in the prevention of strokes and the use of aspirin in the prevention and treatment of cancer.

Professor Elwood talks to ecancertv about opportunities for using aspirin in the treatment of cancer at the 2015 Scientific Conference of the International Aspirin Foundation. In the interview, he also discusses his extensive research experience with the anti-inflammatory drug, including the first evidence that aspirin prevented heart attacks.

Aspirin’s effect on eicosanoid prostaglandins is well documented but exactly how aspirin works is still not clearly defined. Dr Clària talks to ecancer at the Aspirin Foundation meeting about how a novel serious of eicosanoids called aspirin-triggered lipid mediators may be involved in resolving inflammation.

Dr Hongmei Nan talks to ecancertv at the Aspirin Foundation meeting about the need for big, international and collaborative studies for better understanding genetic factors influencing the impact of aspirin on colorectal cancer.

In this interview Dr Din, a Cancer Research UK Clinician Scientist and Honorary Consultant Colorectal Surgeon, discusses her work looking at the use of aspirin as a chemopreventative agent in colorectal cancer (CRC) at the 2015 Scientific Conference of the International Aspirin Foundation. Specifically, she discusses the effects of aspirin and other potential chemopreventative agents on the mTOR signalling pathway. This pathway plays a pivotal role in controlling cell survival and regulating cell metabolism and energy balance and its dysregulation has been implicated in the development of several cancers.

Dr Nan talks to ecancertv at the Aspirin Foundation’s 2015 Scientific Conference about the fact that there is a small subset of people who are not protected from developing colorectal cancer (CRC) by taking aspirin and in whom aspirin may actually be detrimental. Dr Nan is the recipient of the first International Aspirin Foundation junior investigator award.

In this interview at the 2015 Scientific Conference of the International Aspirin Foundation, Dr Lanas discusses his presentation on the mechanisms behind gastrointestinal bleeding complications that can occur with aspirin use. Dr Lanas also outlines his work on the chemoprevention of colorectal cancer (CRC) using aspirin.

Professor Patrono discusses some of his current research at the 2015 Scientific Conference of the International Aspirin Foundation. In the interview he talks about the role of platelet activation and inhibition in diabetes mellitus and myeloproliferative neoplasms, as well as his work investigating how low-dose aspirin works to prevent colorectal cancer.

Patients with HIV treated with highly active retroviral therapy often have a residual risk of non-AIDS-related morbidities, such as cardiovascular disease and cancer. Researchers have thus become interested in seeing if aspirin may help to reduce the heightened state of immune activation observed. In the interview, Dr. Freedman notes that studies are being conducted to determine if aspirin might have a benefit in patients with HIV and comments that it is under-used in patients with concomitant cardiovascular disease when compared to non-HIV infected patients.

In this interview inflammation at the 2015 Scientific Conference of the International Aspirin Foundation, Dr Chan discusses the use of aspirin for the primary prevention of cancer. In the interview he also discusses his research in the area including research presented at the American Association of Cancer Research in 2015, and future research plans with regards to aspirin use.